Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic disorders, such as diabetes. It offers its lead product candidate, BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. The company was founded by Thomas Butler and Ramses Erdtmann in August 2017 and is headquartered in Redwood City, CA.
相关临床试验
10
3 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2017
进行中（未招募）
3
30.0%
已完成
4
40.0%
招募中
1
10.0%
终止
2
20.0%
暂无批准数据
- Biomea Fusion presented COVALENT-111 study results showing icovamenib, a menin inhibitor, demonstrated durable glycemic and C-peptide improvements in insulin-deficient type 2 diabetes patients nine months after the last dose. - The investigational drug showed higher HbA1c reduction associated with higher exposure levels and improved long-term insulin secretion in severe insulin-deficient T2D patients. - Icovamenib was generally well-tolerated with no adverse-event related discontinuations and no related serious adverse events, representing a first-in-class approach targeting beta-cell restoration. - The company plans to initiate Phase IIb trial COVALENT-211 in severe insulin-deficient type 2 diabetes patients and Phase II trial COVALENT-212 with GLP-1 therapy in Q4 2025.
- Biomea Fusion's icovamenib demonstrated durable 1.5% HbA1c reduction at 52 weeks in severe insulin-deficient diabetes patients, nine months after completing just 12 weeks of dosing. - The company initiated Phase I dosing of BMF-650, its next-generation oral GLP-1 receptor agonist for obesity, following promising preclinical data in nonhuman primates. - Preclinical combination studies showed icovamenib plus semaglutide achieved superior glycemic control and body weight reduction while preserving lean mass compared to semaglutide alone. - Biomea raised approximately $68 million in gross proceeds through public offerings, extending its cash runway into the first quarter of 2027.
- Biomea Fusion's experimental drug icovamenib demonstrated sustained blood sugar control in type 2 diabetes patients, with effects persisting nine months after treatment discontinuation. - The drug showed particular promise for patients not responding to GLP-1 therapies like Ozempic, reducing blood sugar levels by 1.3% compared to placebo in this difficult-to-treat population. - Icovamenib works by partially blocking the menin protein and may help restore natural insulin production, especially in insulin-deficient patients. - The FDA previously placed a clinical hold on trials due to liver toxicity concerns but lifted it in September 2024 after protocol revisions.
- Biomea Fusion's Phase II COVALENT-111 study demonstrates that icovamenib, a menin inhibitor, provides sustained HbA1c reductions lasting nine months after treatment completion in type 2 diabetes patients. - The drug achieved a 1.5% HbA1c reduction (p=0.01) in severe insulin-deficient patients with just 12 weeks of treatment, representing a potential breakthrough for the most difficult-to-treat diabetes population. - Icovamenib also showed clinically meaningful benefits in patients failing to achieve glycemic targets on GLP-1 therapy, with a 1.3% HbA1c reduction (p=0.05) sustained through 52 weeks. - The company plans to initiate Phase IIb trials in both patient populations in Q4 2025, positioning icovamenib as a potential first-in-class non-chronic diabetes therapy.
- DelveInsight's 2025 pipeline report reveals 85+ companies actively developing over 100 therapeutic candidates for Type 1 diabetes treatment, indicating a robust and expanding research landscape. - Key emerging therapies include Vertex Pharmaceuticals' VX-880 stem cell-derived islet cell therapy, Eli Lilly's long-acting insulin Efsitora Alfa in Phase III trials, and Sanofi's frexalimab targeting immune pathways. - Recent clinical developments include Creative Medical Technology's CELZ-201 Phase I/IIa trial and NIDDK's 78-participant study evaluating abrocitinib and ritlecitinib treatments. - The pipeline spans diverse therapeutic approaches from traditional insulin therapies to innovative stem cell treatments and immune system modulators, addressing various aspects of Type 1 diabetes management.
- Biomea Fusion presented new data at ADA 2025 showing icovamenib, an oral menin inhibitor, enhanced glycemic control and weight loss when combined with semaglutide while preserving lean muscle mass in preclinical studies. - The Phase II COVALENT-111 trial demonstrated that icovamenib achieved a 1.0% placebo-adjusted HbA1c reduction and 55% increase in C-peptide in severely insulin-deficient patients at 26 weeks, three months after treatment ended. - Preclinical studies revealed icovamenib promoted healthy muscle morphology and prevented drug-induced muscle atrophy, suggesting potential muscle-protective effects when combined with GLP-1 receptor agonists. - The combination therapy approach may allow for lower GLP-1 doses while maintaining efficacy, potentially improving tolerability and offering a new treatment paradigm for type 2 diabetes patients.
- Biomea Fusion's oral GLP-1 receptor agonist BMF-650 achieved 12% and 15% weight reduction in obese cynomolgus monkeys over 28 days at doses of 10 mg/kg and 30 mg/kg respectively. - The study showed dose-dependent appetite suppression with daily food intake reduced to 35g/day and 16g/day compared to 109g/day in control groups. - The company plans to file an Investigational New Drug application in the second half of 2025, with Phase I trials in obese volunteers anticipated for late 2025. - BMF-650 is designed as a next-generation oral small molecule with enhanced pharmacokinetic properties and improved bioavailability compared to injectable GLP-1 therapies.
- Preliminary data from the COVALENT-103 Phase I trial reveals BMF-500, a covalent FLT3 inhibitor, demonstrates clinical activity in heavily pretreated relapsed/refractory acute leukemia patients, with 81.8% of evaluable patients showing response. - The investigational drug was well-tolerated with no dose-limiting toxicities, while showing median overall survival of 3.48 months, exceeding the historical benchmark of 2.1 months for patients resistant to prior FLT3 inhibitor therapy. - Despite Biomea Fusion's strategic pivot toward metabolic diseases, the company is actively seeking partnerships to advance BMF-500's development for patients with limited treatment options in acute leukemia.
- Biomea Fusion shifts strategic focus to diabetes and obesity medicines, with icovamenib and BMF-650 as core assets. - Icovamenib demonstrated a placebo-adjusted 1.5% mean reduction in HbA1c in insulin-deficient type 2 diabetes patients. - The company plans to initiate Phase 2/3 trials for icovamenib in insulin-deficient patients and in combination with GLP-1 therapies. - Preclinical data suggest icovamenib enhances GLP-1-based therapies, improving glycemic control and beta cell function.
- Icovamenib met the primary endpoint in the COVALENT-111 trial, demonstrating a statistically significant, placebo-corrected reduction in HbA1c levels in type 2 diabetes patients. - Patients with beta-cell deficient diabetes achieved a substantial 1.47% placebo-adjusted mean reduction in HbA1c after 12 weeks of treatment with 100 mg icovamenib. - The Phase II study indicated that icovamenib was well-tolerated, with no serious adverse events, hypoglycemic events, or adverse-event related discontinuations reported. - Biomea Fusion plans to engage with the FDA to discuss further development of icovamenib as a first-in-class menin inhibitor for type 2 diabetes.
